News
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
Danish pharmaceutical company Novo Nordisk (NYSE: NVO) just made the headlines for something other than Ozempic. Well, sort of. One of the company's subsidiaries, Novo Holdings, is responsible for
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Investing in healthcare stocks can be a fantastic way to diversify your portfolio with businesses that generate steady growth in a wide range of market environments. Not all healthcare stocks are
3 Stocks That Could Trounce the Market in 2024
Arguably the most important quality for any stock is whether or not it beats the market. If it doesn't, you'd be better off putting your money in an index fund.
Three Motley Fool contributors think
Could Vertex Pharmaceuticals Reach $500 in 2024?
Vertex Pharmaceuticals (NASDAQ: VRTX) soared 85% over the past two years as it headed into a new era of growth. The company already has been a giant in the area of cystic fibrosis (CF) treatment for
EQS-News: The Supervisory Board of Sartorius AG proposes a dividend of 0.74 euros per preference share
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?
Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk. Ozempic addresses
EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24
DexCom (DXCM) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
DexCom (NASDAQ: DXCM)Q4 2023 Earnings CallFeb 08, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
January was a big month for pharmaceutical stocks, with Merck (NYSE: MRK), Eli Lilly (NYSE: LLY), and Novo Nordisk (NYSE: NVO) all climbing 11%, according to data provided by S&P Global Market
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
AstraZeneca Plc (NASDAQ: AZN)Q4 2023 Earnings CallFeb 08, 2024, 6:45 a.m. ET
Andy Barnett
Source Fool.com
Why Advanced Drainage Stock Is Floating Higher Today
Advanced Drainage Systems (NYSE: WMS) beat top- and bottom-line expectations for the quarter, and announced a dividend hike. Investment dollars are flowing into the stock, sending shares of the
Prediction: 2 Stocks That Could Trounce the Market
Every investor wants to beat the market, but doing so is notoriously difficult. That's why many settle for matching the performance of some prominent index by buying the appropriate exchange-traded
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders know just how good it can be to ride a biopharma stock upward as it notches positive milestones year after year. With its shares up by 99% in the
Is AT&T Stock a Buy for 2024?
With 2024 upon us, telecom stalwart AT&T (NYSE: T) looks like it's turned a corner on a multi-year transformation. After John Stankey took over as CEO in July 2020, he refocused the company on its
2 Healthcare Stocks to Buy Hand Over Fist in February
Many investors believe in the January Effect, or the idea that the stock market tends to go on a run during the first month of the year. Whether or not this effect is real, investing in a company
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood trounced the market in 2020, with her aggressive investing style helping Ark Invest's family of exchange-traded funds outperform. She beat the market again in 2023 after back-to-back
Pfizer's Problems Go Far Beyond Just Declining COVID Revenue
A lot can change on the stock market in just a few years, and Pfizer (NYSE: PFE) is a great example. At the end of 2021, its shares were trading at around $60, and things were looking great for the
EQS-News: Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q4 2023 Earnings CallFeb 06, 2024, 5:00 p.m. ET
Operator
Source Fool.com
EQS-Adhoc: SARTORIUS AG: Sartorius successfully completes placement of 200 million euros of treasury preference shares
Why Coherus BioSciences Stock Jumped Today
Shares of Coherus BioSciences (NASDAQ: CHRS) climbed 14.9% on Tuesday after the company announced a positive revision to the terms of its loan agreement with Pharmakon Advisors.
In a press release
Centene (CNC) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Centene (NYSE: CNC)Q4 2023 Earnings CallFeb 06, 2024, 8:30 a.m. ET
Operator
Source Fool.com
EQS-Adhoc: SARTORIUS AG: Sartorius launches placement of up to 200 million euros of treasury preference shares through accelerated bookbuilding
Where Will AT&T Stock Be in 2024?
Fool.com contributor Parkev Tatevosian highlights where be believes AT&T (NYSE: T) stock could be in one year.
*Stock prices used were the afternoon prices of Feb. 3, 2024. The video was published
Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest
Vertex Pharmaceuticals (NASDAQ: VRTX) has a knack for finding profitable niches, and it looks like it's on track to do so again in the field of pain relief. With the latest clinical-trial data